



Prevention of Drug Interaction in Geriatric Patients

Dr. Mrs. S.A. Surale -Patil,

Asst. Professor, Krishna Institute of Medical Sciences,
Karad, Maharashtra, smitaasp73@gmail.com

Dr. Mrs. P. S. Salve,

Asst. Professor, Krishna Institute of Medical Sciences,
Karad, Maharashtra

***Dr. Lekhika Singh,**

Asst. Professor, Krishna Institute of Medical Sciences,
Karad, Maharashtra

Dr. Aditya Shah,

Asst. Professor, Krishna Institute of Medical Sciences,
Karad, Maharashtra

Dr. Mrs A. R. Shinde,

Asst. Professor, Krishna Institute of Medical Sciences,
Karad, Maharashtra

Abstract:

Invasive illnesses pose a significant medical concern in Geriatric individuals because they are increasingly considerably encountered in elderly individuals compared to children and teenagers. In fact, illnesses in seniors might manifest unconventionally and are frequently linked to greater death and disability. Furthermore, multiple medication strategies are frequently used for managing seniors, therefore raising the risk of adverse reactions to medications whenever an antibiotic is prescribed. Throughout aging, bioavailability or pharmaceutical dynamics may be impacted by a steady decline in the operational capability of numerous tissues. Age-related modifications to the physique, decreased volume of liver and circulation, and a decrease in renal elimination may have an impact on both pharmaceutical kinetics and pharmaceutical dynamics. While giving antibiotics to elderly individuals consuming several medications, such concerns ought to be paid consideration.

There are currently recommended measures to increase the security and suitability of prescribed antibiotics. Physician-targeted training programs could boost the prescribing of antibiotics. Governance of antimicrobial initiatives is proven to shorten hospitalizations and increase the quality of life for patients, therefore it would be worthwhile to explore their

usage in institutional settings. The impact of encounters and associated expenditure can also be minimized through computerized administration and advisory platforms, and additional initiatives focused on enhancing antibiotic dose in the context of kidney health.

Keywords: Geriatric patients, Kidney, Medication, Drug interaction

Introduction:

Interactions between pharmaceuticals refer to modifications in the efficiency of a medication or hazard brought about by the use of an additional medicine around the same time. This adjustment is primarily measurable i.e., the magnitude of one's reaction to a medicine is perhaps raised or diminished. Drug-drug interactions (DDIs) can be caused by pharmacological procedures in which the additional medication alters the first medicine's transport to the region of conduct, or by physicochemical techniques, in which both substances operate on identical or comparable targets in a complementary or resentful manner. Pharmaceuticals regarding treacherous dose-effect relationships curves or minimized medicinal indices, those that trigger or block microsomal enzymes, those that comply with no-order eradication dynamics, those administered to critically ill patients, those alongside grave kidney failure or liver dysfunction, as well as seniors who are taking numerous medications all transport the risk of potentially harmful DDR's [1].

Mature aging various morbidities, and polypharmacotherapy are the main contributing causes to the development of harmful effects of improper mixtures of drugs [2]. According to estimates, between 30 and 40 percent of adults over 65 in affluent nations use five or more medications, whereas 12 percent of individuals in the aforementioned age range consume more than ten different medications [2]. Owing to the intricate nature of the course of therapy and their greater likelihood of interacting with different members of the medical establishment, individuals who are suffering from the simultaneous presence of numerous long-term illnesses are prone to experience interactions between medications [3]. Because of modifications caused by age in the bioavailability and physicochemical administration of medications that either enhance or reduce such individuals' susceptibility to pharmaceuticals, medication management in seniors becomes especially difficult [4].

Prescribing possibly incorrect medicines (PIMs) to older adults who have been subjected to several medicines is a problem. PIMs refer to drugs that possess a variety of features, such as those which make them possibly unsuitable for the majority of seniors, for elderly people with specific illnesses, to be utilized with prudence, for probably significant DDI to be circumvented in more elderly adults, and for drugs that ought to be circumvented or designated amount minimized because of renal status [5]. It needs to be remembered since Beer's categorization simply takes just a handful of conceivably serious relationships into account when discussing DDI. Because of this, Beer's parameters understate the number of medically pertinent associations in seniors [5]. Given regard to any DDI that affects older people in broad terms, DDI that explicitly uses PIM as an adjunct medication is problematic

because certain DDI may intensify inherent incorrect characteristics. In fact, the reduction in the breakdown of drugs or solute carrier-dependent clearance raises a PIM's cumulative presence and could raise the likelihood and extent of Adverse Drug Reactions as well as their impact (such as lethality and/or re-hospitalization). As a result, the high incidence of DDI happening notably using PIM as culprit medication in senior individuals deserves to be regarded as an issue of national significance along with the importance to the medical community in calling their focus regarding this particular DDI.

Metabolic Processes in Older People

Important shifts in the makeup of the body and anatomical reduction in the performance of the majority of functions are two characteristics of advancing age. Age-related changes in the body's overall water and fat composition decline, which when coupled with a loss in endurance can cause a condition known as sarcopenia and alter how medicines are distributed [6]. According to estimates, men and women above the age limit of 70 have fat percentages of roughly twenty-five percent and forty percent, respectively, meaning they have 1.5 times greater than the average of adolescents between 20 to 29 [7]. As a consequence, seniors have a more widespread amount of lipophilic medications. Additionally, as people age, their bodily level of water gradually decreases, resulting in a reduction in the amount whereby hydrophilic chemicals distributed [8]. Men show a steady loss of entire body water of 0.3 kg annually through their teenage years until their senior years of 79–80, but women's total bodily water stays largely unchanged from adolescence until the range of 70, at which point they experience a loss of 0.7 kg per year [9].

Two of the greatest pharmacological modifications are the diminished metabolic rate in the liver and a reduction in kidney emptying capability. Elimination of hydrophilic chemicals via the renal system could be greatly hampered as a result of a reduction in the glandular ability of the renal system, necessitating correction of hepatic characteristics and medication dosage [10]. The breakdown of drugs may be impacted by modifications to the hepatic as it ages in a variety of manners. The liver's capacity shrinks around 20–40% in terms of volume as we grow older, whereas blood circulation through the organ's walls declines by 40–60%. Cytochrome P450 (CYP450) oxidase efficiency can decline by as much as thirty percent in older persons in comparison to younger individuals [11].

Additionally, the quantity of plasma protein levels, such as albumin and alpha-1 acid glycoprotein, fluctuates with maturity [12]. These proteins' primary functions in the circulatory system are carrying and storing the majority of foreign and indigenous chemicals. The typical albumin concentration among the old populace is 19% albumin among the old populace is 19% which is less than among younger individuals. Even when the overall amount of the drug falls below the beneficial limit, an elevated unbound drug level of compounds firmly attached to albumin may be a possible source of poisoning [13].

Propranolol intake may rise due to a modest rise in alpha-1 acid glycoprotein, which is seen in robust old people although is less apparent in those who have a condition [14]. Investigations additionally showed reduced concentrations of p-glycoprotein in aged subjects'

cerebral and gastrointestinal cells, particularly when Alzheimer's is present [15,16]. The membrane-associated protein moves a variety of substances, particularly medications like steroids or cardiovascular glycosides like digoxin, through the outer layer of a cell.

A decline in metabolic processes in cells, that can dramatically lessen the effect of chemicals given in the manner of prodrugs, is an additional noteworthy shift seen in the aged [17].

Irrespective of how the molecular structure of a chemical is distributed in cells, pharmacodynamic alterations occur as well and are linked to modifications in drug responsiveness [10,11]. The following is demonstrated by the fact that older people have decreased cardiac responsiveness to beta-adrenoreceptor antagonists and agonists as well as a spike in the occurrence of orthostatic low blood pressure events following treatment with antihypertensive drugs.

Additionally, older individuals' neurological systems become increasingly vulnerable to substances that affect the functioning of the brain, such as opioids, benzodiazepines, and psychiatric medicines [6].

Reverberations of Interactions of Pharmaceuticals:

Pharmaceutical Interaction' influence on Lifespan

Mortality is among the most catastrophic effect of unfavorable interactions between drugs [18].

Individuals who use unusual medicine formulations experience a 1.6-fold higher death rate, according to research conducted in the US [19]. Significantly, irrespective of the number of medications, adding further poorly matched drugs is linked to a 39% absolute boost in death [20]. Inappropriate mixtures of drugs that enhance the likelihood of crashes in seniors (STOPP guidelines version 2, category K), such as benzodiazepines, neuroleptics, and hypnotic medications belonging to the Z category, were found to have an especially significant connection with death [21].

Pharmaceutical Interactions' Effects on Life Quality

The umbrella term of health-associated aspects of life (HRQoL) comprises an individual's personal evaluation of their level of capability to engage in vital actions which are influenced by their present condition [22]. Prior research has found a link between taking a lot of medications, probable pharmaceutical connections, and a decreased quality of life [23]. On the EQ-VAS magnitude, these patients' medical quality of life self-evaluation ratings were substantially lower [24]. The impact was made worse by a concurrent decline in endurance, flexibility, and memory capacity [24,25].

Effect of Pharmaceutical Interactions on Readmission Hospital Rates

One of the greatest frequent reasons for hospitalization in senior citizens is complications brought on by pharmaceutical interactions [26]. Statewide observational research in the US found that 99,628 incidents of unexpected hospitalizations owing to pharmacological side

effects occur annually [27]. Despite the identical reasoning, there were almost 4.3 million admissions to multiple hospitals in 2005 [28]. Hospital readmission rates might be prevented in just two out of every three instances, according to estimates [26].

Monetary Expenses as a Result of Pharmaceutical Interactions

Around 200 billion dollars is thought to be spent annually across the nation on healthcare for older people as a result of healthcare mistakes and adverse effects [29]. This tendency has become a major issue in European nations [30–32]. Individual assistance clients and all of the medical systems are financially burdened by numerous trips to ERs and outpatient centers, readmissions, and the expense of several pharmaceuticals [2].

Ways to Prevent Pharmaceutical Interactions in Geriatric Patients:

The understanding of age-related processes is expanding as a result of studies done by experts in gerontological studies and geriatric medicine. The primary vulnerabilities for pharmaceutical interactions are being identified via deeper analysis, making it far easier to pinpoint individuals who are especially vulnerable to ADRs. Additionally, there is a lack of recognition of the effects of pharmaceutical relationships, that interrupt the course of therapy, add to the cost strain on medical facilities, and further negatively impact the wellness of individuals but also their way of living life.

An erroneous prescribing accounts for 80% of major pharmacological adverse reactions, according to earlier research. In addition, 87.9% of these occurrences are typically possibly predicted and preventable [18]. There are numerous standardized instruments accessible to help with medication management, appropriate to each aging person's requirements and ability. Certain of them, such as the Beers parameters and STOPP standards (evaluating tool to identify possibly improper medicines for elderly patients), provide straightforward recommendations for medicines that are appropriate and inappropriate for use in elderly individuals and START (evaluating tool to prompt physicians to prescribe the proper course of action) [33]. Numerous nations have conducted in-depth studies on their effectiveness, which shows the superiority of STOPP/START parameters for recognizing harmful medicines [34]. STOPP/START criteria, in contrast to Beers' criteria, were developed as an assessment, therefore these are frequently used in therapeutic studies as well as a component of investigation methodologies [2].

Furthermore, it highlights the importance of medicinal chemists, whose efforts may recognize and reduce issues brought on by improper medication. This approach has proven effectively used for several decades in the US, the UK, and many other European nations, improving the healing process and ushering in financial gains [35]. A possible technique to improve medication interface detection involves the computerized evaluation of interaction methods. Together with the digitization of wellness infrastructure, a variety of specialized programs are accessible worldwide. These include internet-based resources, smartphone software components, and even inclusion in health-related data networks like the SureScripts program in the US [36].

Regrettably, it is believed weak warning precision can pose a significant barrier to the successful implementation of knowledge and a genuine improvement in the security of patients while medication [37].

Statistics from a vast majority of jurisdictions across the globe continue to demonstrate a disturbingly large proportion of improper mixtures of drugs in older people, although substantial studies and decades of expertise. Which possible causes may there be regarding this occurrence?

Some studies highlight the flaws in the particular standards for medications not recommended for use in elderly people, viewing them as rigid and failing to take into consideration all of the aspects affecting the provision of excellent quality, individualized treatment [38]. Randomized research investigations that reveal the side effects connected to certain medications frequently omit seniors [38].

As a result, however, is a dearth of reliable information regarding the associated hazards and advantages of treatment interventions in these kinds of patients [39].

The senior citizen population is very heterogeneous, according to certain experts, therefore the balance between risk and benefit will change based on the individual's medical status [39]. The elderly who have many illnesses must follow complicated therapies. Although there is no proof that treatment has an adverse impact, clinicians may be reticent to alter an effective plan [38]. An individual who isn't responding to or struggles with the chosen treatment may benefit from alternatives that have been designated as undesirable in elderly individuals [39]. Furthermore, selecting a certain treatment frequently involves considering the expense of the treatment [39]. If the advantages surpass the hazards to the receptive, the administration of pharmaceuticals may occasionally be ethically justifiable [39].

The majority of professionals concur that, instead of serving as the ultimate indicator of the efficacy or standard of medical care, all currently accessible assistance resources to recognize pharmaceutical interactions and unusual mixtures of drugs work best when utilized as a screening tool for recognizing seniors who are at significant risk of receiving inadequate pharmaceutical treatment and to prioritize and recognize problematic regions [39].

Conclusion:

There exists an immediate obligation to take pharmaceutical mistakes into account in ordinary medical procedures owing to the rising expense of medical care to help lessen the strain on the medical sector. Simplifying the prescription process and increasing a prescriber's expertise by training, the utilization of information management mechanisms, and the observation of the results of actions can assist in the decrease of pharmaceutical mistakes. The majority of pharmaceutical mistakes are avoidable; an evaluation of the prescribed medications performed by a skilled medicinal chemist can identify these mistakes, and validation can assist in removing these mistakes prior to the individual consuming them. Therefore, a chemist can fulfill a variety of responsibilities in the social and medical fields to improve healthcare for patients and welfare as well as contribute to upholding medical norms.

References:

1. K. D. Tripathi, Drug interaction. Essentials of Medical Pharmacology, pp. 928–934, 7 edition, Jaypee, Delhi, 2013.
2. Kim, J.; Parish, A.L. Polypharmacy and Medication Management in Older Adults. *Nurs. Clin. N. Am.* **2017**, *52*, 457–468. [[CrossRef](#)]
3. Panagioti, M.; Stokes, J.; Esmail, A.; Coventry, P.; Cheraghi-Sohi, S.; Alam, R.; Bower, P. Multimorbidity and patient safety incidents in primary care: Asystematic review and meta-analysis. *PLoS ONE* **2015**, *10*, e0135947. [[CrossRef](#)] [[PubMed](#)]
4. Zamboni, M.; Rossi, A.P.; Fantin, F.; Zamboni, G.; Chirumbolo, S.; Zoico, E.; Mazzali, G. Adipose tissue, diet and aging. *Mech. Ageing Dev.* **2014**, *136–137*, 129–137. [[CrossRef](#)] [[PubMed](#)]
5. 2019 American Geriatrics Society Beers Criteria®Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria®for Potentially Inappropriate Medication Use in Older Adults. *J. Am. Geriatr. Soc.* **2019**, *67*, 674–694. [[CrossRef](#)]
6. Eldesoky, E.S. Pharmacokinetic-pharmacodynamic crisis in the elderly. *Am. J. Ther.* **2007**, *14*, 488–498. [[CrossRef](#)] [[PubMed](#)]
7. Meeuwssen, S.; Horgan, G.W.; Elia, M. The relationship between BMI and percent body fat, measured by bioelectrical impedance, in a large adult sample is curvilinear and influenced by age and sex. *Clin. Nutr.* **2010**, *29*, 560–566. [[CrossRef](#)] [[PubMed](#)]
8. Pea, F. Pharmacokinetics and drug metabolism of antibiotics in the elderly. *Expert Opin. Drug Metab. Toxicol.* **2018**, *14*, 1087–1100. [[CrossRef](#)]
9. Schoeller, D.A. Changes in total body water with age. *Am. J. Clin. Nutr.* **1989**, *50*, 1176–1181. [[CrossRef](#)]
10. Bolignano, D.; Mattace-Raso, F.; Sijbrands, E.J.G.; Zoccali, C. The aging kidney revisited: A systematic review. *Ageing Res. Rev.* **2014**, *14*, 65–80. [[CrossRef](#)] [[PubMed](#)]
11. Tan, J.L.; Eastment, J.G.; Poudel, A.; Hubbard, R.E. Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. *Drugs Aging* **2015**, *32*, 999–1008. [[CrossRef](#)]
12. Bteich, M. An overview of albumin and alpha-1-acid glycoprotein main characteristics: Highlighting the roles of amino acids in binding kinetics and molecular interactions. *Heliyon* **2019**, *5*, e02879. [[CrossRef](#)] [[PubMed](#)]
13. Valerio, C.; Theocharidou, E.; Davenport, A.; Agarwal, B. Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. *World J. Hepatol.* **2016**, *8*, 345. [[CrossRef](#)] [[PubMed](#)]
14. Woo, J.; Chan, H.S.; Or, K.H.; Arumanayagam, M. Effect of age and disease on two drug binding proteins: Albumin and α -1-acid glycoprotein. *Clin. Biochem.* **1994**, *27*, 289–292. [[CrossRef](#)]
15. Haran, J.P.; Bhattarai, S.K.; Foley, S.E.; Dutta, P.; Ward, D.V.; Bucci, V.; McCormick, B.A.; Gilbert, J.; Faith, J. Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway. *mBio* **2019**, *10*. [[CrossRef](#)]

16. Chiu, C.; Miller, M.C.; Monahan, R.; Osgood, D.P.; Stopa, E.G.; Silverberg, G.D. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: Preliminary observations. *Neurobiol. Aging* **2015**, *36*, 2475–2482. [[CrossRef](#)] [[PubMed](#)]
17. Huttunen, K.M.; Raunio, H.; Rautio, J. Prodrugs—From Serendipity to Rational Design. *Pharmacol. Rev.* **2011**, *63*, 750–771. [[CrossRef](#)]
18. Buajordet, I.; Ebbesen, J.; Erikssen, J.; Brørs, O.; Hilberg, T. Fatal adverse drug events: The paradox of drug treatment. *J. Intern. Med.* **2001**, *250*, 327–341. [[CrossRef](#)]
19. Muhlack, D.C.; Hoppe, L.K.; Weberpals, J.; Brenner, H.; Schöttker, B. The Association of Potentially Inappropriate Medication at Older Age with Cardiovascular Events and Overall Mortality: A Systematic Review and Meta-Analysis of Cohort Studies. *J. Am. Med. Dir. Assoc.* **2017**, *18*, 211–220. [[CrossRef](#)]
20. Wauters, M.; Elseviers, M.; Vaes, B.; Degryse, J.; Dalleur, O.; Vander Stichele, R.; Christiaens, T.; Azermai, M. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. *Br. J. Clin. Pharmacol.* **2016**, *82*, 1382–1392. [[CrossRef](#)]
21. Counter, D.; Millar, J.W.T.; McLay, J.S. Hospital readmissions, mortality and potentially inappropriate prescribing: A retrospective study of older adults discharged from hospital. *Br. J. Clin. Pharmacol.* **2018**, *84*, 1757–1763. [[CrossRef](#)]
22. Fitzpatrick, R. The International Assessment of Health-related Quality of Life: Theory, Translation, Measurement and Analysis. *J. Med. Ethics* **1996**, *22*, 248–249. [[CrossRef](#)]
23. Montiel-Luque, A.; Núñez-Montenegro, A.J.; Martín-Aurioles, E.; Canca-Sánchez, J.C.; Toro-Toro, M.C.; González-Correa, J.A. Medication-related factors associated with health-related quality of life in patients older than 65 years with polypharmacy. *PLoS ONE* **2017**, *12*, e0171320. [[CrossRef](#)] [[PubMed](#)]
24. Verde, Z.; De Diego, L.G.; Chicharro, L.M.; Bandrés, F.; Velasco, V.; Mingo, T.; Fernández-Araque, A.; De Diego, G.; Araque, F. Physical performance and quality of life in older adults: Is there any association between them and potential drug interactions in poly medicated octogenarians. *Int. J. Environ. Res. Public Health* **2019**, *16*, 4190. [[CrossRef](#)] [[PubMed](#)]
25. Maher, R.L.; Hanlon, J.; Hajjar, E.R. Clinical consequences of polypharmacy in elderly. *Expert Opin. Drug Saf.* **2014**, *13*, 57–65. [[CrossRef](#)] [[PubMed](#)]
26. Patel, N.S.; Patel, T.K.; Patel, P.B.; Naik, V.N.; Tripathi, C. Hospitalizations due to preventable adverse reactions—A systematic review. *Eur. J. Clin. Pharmacol.* **2017**, *73*, 385–398. [[CrossRef](#)]
27. Budnitz, D.S.; Lovegrove, M.C.; Shehab, N.; Richards, C.L. Emergency hospitalizations for adverse drug events in older Americans. *N. Engl. J. Med.* **2011**, *365*, 2002–2012. [[CrossRef](#)]

28. Bourgeois, F.T.; Shannon, M.W.; Valim, C.; Mandl, K.D. Adverse drug events in the outpatient setting: An 11-year national analysis. *Pharmacoepidemiol. Drug Saf.* **2010**, *19*, 901–910. [[CrossRef](#)]
29. Informatics II for H. IMS Health Study Identifies \$200+ Billion Annual Opportunity from Using Medicines More Responsibly 2013. Available online: www.theimsinstitute.org (accessed on 19 April 2020).
30. Veeren, J.C.; Weiss, M. Trends in emergency hospital admissions in England due to adverse drug reactions: 2008–2015. *J. Pharm. Heal. Serv. Res.* **2016**, *8*, 5–11. [[CrossRef](#)]
31. Hartholt, K.A.; Van Der Velde, N.; Looman, C.W.N.; Panneman, M.J.M.; Van Beeck, E.F.; Patka, P.; Van Der Cammen, T.J. Adverse drug reactions related hospital admissions in persons aged 60 years and over, the Netherlands, 1981–2007: Less rapid increase, different drugs. *PLoS ONE* **2010**, *5*, e13977. [[CrossRef](#)]
32. Scripcaru, G.; Mateus, C.; Nunes, C. Adverse drug events—Analysis of a decade. A Portuguese case study, from 2004 to 2013 using hospital database. *PLoS ONE* **2017**, *12*, e0178626. [[CrossRef](#)]
33. Hill-Taylor, B.; Walsh, K.A.; Stewart, S.A.; Hayden, J.; Byrne, S.; Sketris, I.S. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: Systematic review and meta-analysis of randomized controlled studies. *J. Clin. Pharm. Ther.* **2016**, *41*, 158–169. [[CrossRef](#)] [[PubMed](#)]
34. Rodrigues, M.C.S.; De Oliveira, C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: An integrative review. *Rev. Lat. Am. Enferm.* **2016**, *24*. [[CrossRef](#)] [[PubMed](#)]
35. Somers, A.; Robays, H.; De Paepe, P.; Van Maele, G.; Pehudo, K.; Petrovic, M. Evaluation of clinical pharmacist recommendations in the geriatric ward of a Belgian university hospital. *Clin. Interv. Aging* **2013**, *8*, 703–709. [[CrossRef](#)] [[PubMed](#)]
36. Skelton, T. Surescripts CEO sees “a much more interconnected and digitized healthcare system” ahead. *Mod. Heal.* **2016**, *46*, 30–31.
37. Glassman, P.A.; Simon, B.; Belperio, P.; Lanto, A. Improving recognition of drug interactions: Benefits and barriers to using automated drug alerts. *Med. Care* **2002**, *40*, 1161–1171. [[CrossRef](#)]
38. Curtis, L.H.; Østbye, T.; Sendersky, V.; Hutchison, S.; Dans, P.E.; Wright, A.; Woosley, R.L.; Schulman, K.A. Inappropriate prescribing for elderly Americans in a large outpatient population. *Arch. Intern. Med.* **2004**, *164*, 1621–1625. [[CrossRef](#)]
39. Zhan, C.; Sangl, J.; Bierman, A.S.; Miller, M.R.; Friedman, B.; Wickizer, S.W.; Meyer, G.S. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey. *JAMA* **2001**, *286*, 2823–2829. [[CrossRef](#)] [[PubMed](#)]